What should I watch when giving magnesium sulfate?

Magnesium Sulfate

Class:	Electrolyte replacement (anticonvulsant, antidysrhythmic)
Actions:	Depresses the central nervous system Depresses skeletal and smooth muscles Decreases amount of acetylcholine in neuromuscular synapses
Indications:	Torsades de pointes (polymorphic ventricular tachycardia)–1st line drug of choice during cardiac arrest Hypomagnesemia
Pharmacokinetics:	Duration: 30 minutes (IV)
Adverse Effects:	Flushing, sweating, extreme thirst, sedation, confusion Depressed reflexes, flaccid paralysis, respiratory paralysis Heart block, cardiac arrest
Signs of Toxicity:	Paralysis Cardiac arrest Hypermagnesemia (weakness, depressed reflexes, paralysis)
Contraindications:	Myocardial damage Heart blocks In pregnancy, IV administration during 2 hours before delivery Safety during pregnancy (Category A).
Dosages & Routes:	IV bolus: (for dysrhythmias or hypomagnesemia) Torsades de pointes during cardiac arrest: 1-2 gm diluted to 10 ml with D5W IV or IO over 5 – 20 minutes. Torsades de pointes with pulse or hypomagnesemia: 1-2 gm in 50-100 ml D5W IV infusion over 5 – 60 minutes. Follow with 0.5 – 1 gm/hour titrated to control torsades.
Nursing Implications:	Drug Interactions: Drug Incompatibilities: Check serum magnesium level prior to administration. Cardiac monitor should be used on patients receiving MgSO4 intravenously. Have injectable form of calcium gluconate available to reverse paralyzing effects of magnesium sulfate. Blood pressure may drop if MgSO4 is administered too rapidly. Check blood pressure and pulse every 10-15 minutes during therapy. Normal serum plasma level of MgSO4 is 1.8 – 3.0 mEq/L. Respiratory paralysis occurs at 12-15 mEq/L. Cardiac arrest occurs at 25 mEq/L. Assess patellar reflexes hourly to monitor for evidence of toxicity. Monitor hourly urine output. Do not breast feed while receiving MgSO4.

References:

American Heart Association. (2006). Handbook of Emergency Cardiac Care (p. 57). Salem, MA: AHA.

Dirks, J.L. (2010) Cardiovascular therapeutic management. In L.D. Urden, K.M. Stacy, & M.E. Lough's (Eds.) Critical care nursing: Diagnosis and management (6th ed., p. 550). St. Louis: Mosby Elsevier.

Lehne, R.A. (2010). Pharmacology for nursing care (7th ed., pp. 458-459). St. Louis: Saunders Elsevier.

Wilson, B.A., Shannon, M.T., Shields, K.M., & Stang, C.L. (2007). Prentice Hall Nurse's Drug Guide 2007 (pp. 989-991). Upper Saddle River, NJ: Pearson Prentice Hall.

Back to Cardiac Medications Front Page

Back to Antidysrhythmic Medications Classifications

Magnesium sulfate (magnesium sulfate (magnesium sulfate injection) injection) should be given very cautiously in the presence of serious impairment of renal function since it is excreted almost entirely by the kidneys.

The principle hazard in parenteral magnesium therapy is the production of abnormally high levels of magnesium in the plasma. Such high levels may cause flushing, sweating, hypotension, circulatory collapse and depression of cardiac and central nervous system function. The most immediate danger to life is respiratory depression.

During the period of parenteral therapy with magnesium salts, the patient should be watched carefully. A preparation of calcium, such as the gluconate or gluceptate should be at hand for intravenous administration as an antidote.

In the presence of severe renal insufficiency, no more than 20 grams of magnesium should be given within a forty-eight hour period. In eclampsia, however, renal function is not seriously impaired and magnesium may be more rapidly excreted.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

When barbiturates, narcotics, or other hypnotics (or systemic anesthetics) are to be given in conjunction with magnesium, their dosage should be adjusted with caution because of the additive central depressive effects of magnesium.

Pregnancy - Teratogenic effects: Pregnancy category C. Animal reproduction studies have not been conducted with Magnesium Sulfate Injection, USP 50%. It is also not known whether Magnesium Sulfate Injection, USP 50% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium Sulfate Injection, USP 50% should be given to a pregnant woman only if clearly needed.

Internet Citation: Safe Medication Administration: Magnesium Sulfate. Content last reviewed November 2018. Agency for Healthcare Research and Quality, Rockville, MD.
https://www.ahrq.gov/hai/tools/perinatal-care/modules/strategies/medication/tool-safe-mgso4.html

Problem: The Institute for Safe Medication Practices (ISMP) has published descriptions of events related to magnesium overdoses.1 Most of the errors were a result of misprogrammed pumps, unfamiliarity with safe doses and signs of magnesium toxicity, inadequate monitoring, and mixups between magnesium and oxytocin. An example follows.

A 27-year-old pregnant woman was admitted to a labor-and-delivery unit with cramping, abdominal pain, vaginal bleeding, and leakage of amniotic fluid. Although she was only 27 weeks pregnant, an examination showed that she was in the early stages of labor with a breech baby. In an attempt to stop the preterm labor from progressing, the obstetrician prescribed intravenous (IV) magnesium sulfate, with a bolus dose of 6 g over 30 minutes, followed by a continuous infusion of 2 g/hour.

The patient’s nurse obtained a 20-g/500-mL bag of magnesium sulfate from an automated dispensing cabinet. The nurse was unfamiliar with programming a bolus dose using the software in the smart infusion pump. The bolus dose feature allows the user to program the pump to deliver a bolus dose (6 g/30 minutes) and then automatically switches to deliver a continuous infusion (2 g/hour) after the bolus dose has been administered.

Not knowing how to use this feature, the nurse programmed the bolus to be delivered as a continuous infusion at 12 g/hour. The pump did not provide a “hard stop” to guard against an excessive dose of magnesium during continuous infusion. The nurse intended to return to the patient’s room in 30 minutes to reprogram the pump to deliver 2 g/hour. However, she was distracted by other responsibilities and failed to return to the patient’s room to adjust the infusion rate as planned.

The patient became flushed and short of breath, and she called for a nurse. When the nurse arrived, the patient also complained of dizziness and was found to be hypotensive. She quickly became unresponsive, requiring brief cardiopulmonary resuscitation. Magnesium toxicity was suspected, and the infusion was stopped. The patient was given a rescue dose of IV calcium. Laboratory results confirmed a supratherapeutic magnesium blood level.

Fortunately, the patient responded to emergency treatment. The baby was delivered by cesarean section several days after the event because of unrelated pre-term complications. Both the mother and child were eventually discharged with no permanent harm.

Safe Practice Recommendations: To avoid serious adverse effects from IV magnesium sulfate, bolus doses should not exceed 6 g over a 15- to 20-minute period, and continuous infusion rates should not exceed 3 g/hour. In this case, the infusion ran at 12 g/hour for more than 1 hour. The following measures should be instituted to avoid unnecessary harm from IV magnesium sulfate bolus doses.

The dose should never be infused from the maintenance solution unless all of these criteria are consistently met:
1. The bolus is delivered via the bolus dose feature with a smart infusion pump that allows programming of both the bolus dose and continuous infusion rate. When the bolus dose has been administered, there is an automatic switch to the continuous infusion rate.
2. Separate dose limits have been set for bolus doses of magnesium sulfate (e.g., 6 g/30 minutes) and maintenance doses (e.g., 3 g/hour).
3. These dose limit alerts remain operational at all times.
4. The alerts are configured as a hard stop, which forces the user to reprogram the infusion if the dose exceeds safe limits.
5. A qualified nurse remains at the bedside during infusion of the bolus dose to monitor the patient for signs of magnesium toxicity.
If these five conditions are not consistently met, the ISMP recommends administering the bolus dose from a separate container prepared by the pharmacy. A commercially available 4-g minibag can also be used if a 4-g bolus dose is prescribed.
If the five conditions are consistently met, all users of smart pumps must have received training to program the pump—including bolus doses—and they must be able to demonstrate ongoing competency. Bypassing the bolus dose functionality or employing a “generic” setting on a smart pump is unsafe.
For maintenance solutions, the ISMP recommends using only the 20-g/500-mL bags of magnesium sulfate, not the 40-g/1,000-mL bags. The 500-mL bag is easier to differentiate from liter bags of hydrating solutions and medications used during labor and delivery. The smaller volume also helps limit the amount of magnesium that a patient could receive if a rapid infusion occurs accidentally.
For added safety, some organizations only use the 4-g minibags for maintenance infusions, which call for frequent bag changes, but they limit the amount of drug that the patient can receive if an error occurs. Some facilities also require an independent double-check of pump settings before magnesium (bolus and maintenance) infusions are started.
During IV magnesium administration, the patient’s vital signs, oxygen saturation, deep tendon reflexes, level of consciousness, and fetal heart rate characteristics with maternal uterine activity should be frequently monitored. While giving a bolus dose, a nurse should remain at the bedside to monitor the patient and to watch for clinical manifestations of magnesium toxicity.
Generalized neuromuscular abnormalities, visual changes, facial flushing, nausea, somnolence, and weakness are often initial presenting symptoms, which can progress to hypotension (refractive to vasopressors or volume expanders); muscle paralysis; coma; hypo active tendon reflexes; respiratory failure; paradoxical bradycardia; a prolonged PR, QRS, and QT interval; and complete heart block, cardiac arrest, or both.
If symptoms of magnesium toxicity are present, the patient should be treated immediately and the possibility of an error should be investigated.
Calcium gluconate should be stocked nearby with directions for use if respiratory depression occurs.
Staffing patterns should allow time for proper monitoring, and protocols should include periodic monitoring of magnesium blood levels.
When magnesium sulfate is discontinued, the bag and tubing should be removed immediately and discarded to avoid potential mixups with other IV fluids and medications.
Staff members should not be misled by a solid safety record in their labor-and-delivery unit. Complacency with using IV magnesium sulfate could eventually lead to a tragedy. All hospitals and birthing centers that offer obstetrical services should not delay in implementing these error-reduction strategies.